Ryan Lingle, DO
Family Medicine · la Porte, INNPI 1891290631
Payments from drug & device makers
Across 176 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$524
- AbbVie$320
- Pfizer$253
- Lilly USA, LLC$215
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$195
- GSK$138
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,074100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $524 |
| AbbVie | 16 | $320 |
| Pfizer | 17 | $253 |
| Lilly USA, LLC | 10 | $215 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $195 |
| GSK | 9 | $138 |
| Supernus Pharmaceuticals, Inc. | 2 | $138 |
| Amgen | 9 | $134 |
| Bayer | 7 | $125 |
| Lundbeck LLC | 5 | $112 |
| Otsuka America Pharmaceutical, Inc. | 6 | $107 |
| Astellas Pharma US Inc | 6 | $95 |
| Mylan Specialty L.p. | 4 | $94 |
| Vanda Pharmaceuticals Inc. | 2 | $71 |
| Phathom Pharmaceuticals, Inc. | 4 | $65 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $61 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Novartis | 3 | $43 |
| Dexcom, Inc. | 2 | $37 |
| Exact Sciences | 2 | $32 |
| Nevro Corp. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Merck | 2 | $28 |
| Boehringer Ingelheim | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Intuitive Surgical | 1 | $26 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| Eisai Inc. | 1 | $25 |
| Radius Health, Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$113
How this compares
$3,074 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 133 | $150,116 |
| JardianceEmpagliflozin | 134 | $120,848 |
| TrulicityDulaglutide | 52 | $66,475 |
| MounjaroTirzepatide | 32 | $34,314 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $33,847 |
| EliquisApixaban | 44 | $33,823 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $33,579 |
| RybelsusSemaglutide | 15 | $29,410 |
| FarxigaDapagliflozin Propanediol | 40 | $28,415 |
| JanuviaSitagliptin Phosphate | 35 | $26,983 |
| EntrestoSacubitril/Valsartan | 24 | $18,692 |
| XareltoRivaroxaban | 15 | $15,905 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $11,078 |
| Humalog Kwikpen U-100Insulin Lispro | 26 | $10,113 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $9,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $524 | $179,525148 claims |
| Boehringer IngelheimJardiance | $28 | $120,848134 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $215 | $100,78984 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $138 | $41,83161 claims |
| PfizerEliquis | $253 | $33,82344 claims |
| MerckJanuvia | $28 | $26,98335 claims |
| NovartisEntresto | $43 | $18,69224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in la Porte
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.